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Background: Nitric oxide (NO) is produced as part of the host immune response to bacterial infections, including
urinary tract infections. The enzyme flavohemoglobin, coded by the hmp gene, is involved in protecting bacterial
cells from the toxic effects of NO and represents a potentially interesting target for development of novel
treatment concepts against resistant uropathogenic bacteria. The aim of the present study was to investigate if
the in vitro antibacterial effects of NO can be enhanced by pharmacological modulation of the enzyme
flavohemoglobin.
Results: Four clinical isolates of multidrug-resistant extended-spectrum β-lactamase (ESBL)-producing uropathogenic
E. coli were included in the study. It was shown that the NO-donor substance DETA/NO, but not inactivated DETA/NO,
caused an initial growth inhibition with regrowth noted after 8 h of exposure. An hmp-deficient strain showed a
prolonged growth inhibition in response to DETA/NO compared to the wild type. The imidazole antibiotic miconazole,
that has been shown to inhibit bacterial flavohemoglobin activity, prolonged the DETA/NO-evoked growth inhibition.
When miconazole was combined with polymyxin B nonapeptide (PMBN), in order to increase the bacterial wall
permeability, DETA/NO caused a prolonged bacteriostatic response that lasted for up to 24 h.
Conclusion: An NO-donor in combination with miconazole and PMBN showed enhanced antimicrobial effects and
proved effective against multidrug-resistant ESBL-producing uropathogenic E. coli.
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Nitric oxide (NO) is formed from an inducible form of ni-
tric oxide synthase (iNOS) as part of the host antimicrobial
defence program [1]. Increased iNOS activity has been doc-
umented in the bladder and urine in patients suffering from
urinary tract infection (UTI) [2,3]. The antimicrobial effects
of NO are complex but NO and its autoxidation products
interact with a wide variety of targets including iron-sulfur
thiols, tyrosine residues, lipids and DNA bases [1,4]. NO in-
hibits growth of a wide variety of gram-negative and gram-* Correspondence: katarina.persson@oru.se
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article, unless otherwise stated.positive bacterial species [1]. Growth inhibitory effects on
common urinary pathogens have been reported [5], but
uropathogenic E. coli (UPEC) are less sensitive to NO than
non-pathogenic strains of E. coli [6,7].
To protect against the damage caused by nitrosative
stress, bacteria possess multiple defence mechanisms in-
volving scavengers, detoxifying enzymes and evasion
strategies. Flavohemoglobin, encoded by the hmp gene
[8], is a protein that has been shown to have NO dioxy-
genase activity [8] and be involved in protecting bacterial
cells from nitrosative stress [9,10]. Flavohemoglobin uti-
lizes O2 for NO detoxification and oxidize NO to harm-
less nitrate, which protect the bacteria from the toxic
effect of NO. The significance of flavohemoglobin in
NO-protection has been shown using hmp-deficientCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Summary of the results from the antibiotic
susceptibility testing and the molecular characterization
of the producing CTX-M-types
Isolate CTX-M subgroup CTX-M type Antibiotic resistance
ESBL 1 CTX-M-9 CTX-M-24 CTX, CAZ, CTB, TMP, CIP,
MEL, GEN
ESBL 6 CTX-M-1 CTX-M-15 CTX, CAZ, CTB, TMP, CIP
ESBL 7 CTX-M-1 CTX-M-15 CTX, CAZ, TMP, CIP, MEL
ESBL 9 CTX-M-9 CTX-M-14 CTX, CAZ, TMP, CIP, MEL
Abbreviations: CTX cefotaxime, CAZ ceftazidime, CTB ceftibuten, TMP
trimethoprim, CIP ciprofloxacin, MEL mecillinam, GEN gentamicin.
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stress [8,11]. We have previously shown that UPEC in-
crease flavohemoglobin expression after exposure to NO
and that an hmp-deficient UPEC strain is more sensitive
to NO than a wild type strain [6,12]. The importance of
NO-protection and flavohemoglobin for UPEC coloni-
zation has been addressed in previous studies. UPEC that
had been pre-conditioned to nitrosative stress showed fa-
cilitated colonization of the mouse urinary tract [7] while
an impaired colonization was observed following flavohe-
moglobin gene depletion [12]. Moreover, elevated hmp ex-
pression was found in UPEC isolates isolated from
patients with UTI, suggesting that UPEC isolates face
host-derived nitrosative stress during human UTI and ac-
tivate the NO-detoxifying enzyme flavohemoglobin [12].
Pharmacological inhibition of flavohemoglobin might
represent a new strategy to combat human infections,
including UTI [10]. X-ray structural information has re-
vealed that the flavohemoglobin protein possess large
heme pockets capable of sequestering imidazole antibi-
otics [13]. Antifungal azoles, like miconazole, are able to
inhibit the activity of microbial flavohemoglobin, includ-
ing the NO dioxygenase activity of E. coli [14]. Further-
more, the binding of miconazole to the heme moiety of
flavohemoglobin has been demonstrated to increase the
intracellular oxidative stress and enhanced the anti-
microbial activity against Staphylococcus aureus [15].
During the last decade an increasing prevalence of
extended-spectrum β-lactamase (ESBL)-producing E.
coli has been detected worldwide. Plasmid-mediated β-
lactamase enzymes inactivate β-lactam antibiotics, which
results in ineffective compounds and therapy failure.
The majority of ESBL-producing bacteria are isolated
from urine samples [16,17] and the prevalence of uro-
pathogenic ESBL-producing isolates have increased in
community-acquired UTIs the last decade [18]. The
CTX-M-type β-lactamases are the dominant ESBLs and
the CTX-M family is classified into five major groups
based on similarities in their amino acid sequences [19].
In addition to resistance to most β-lactam antibiotics,
multidrug resistance (i.e. resistance ≥ 3 different anti-
microbial groups) is common [19]. Dissemination of
multidrug-resistant ESBL-producing E. coli may in the
future change uncomplicated, treatable urinary tract in-
fections into life threatening infections and new thera-
peutic options are urgent. Microbial defence enzymes
that enable the bacteria to resist host-derived factors
have emerged as attractive targets for drug development
[20]. Inhibition of factors involved in NO-defence may
find applications as antimicrobial therapy by disable the
bacterial resistance mechanisms and enhance the tox-
icity of host-derived or exogenously administered NO.
The aim of the present study was to investigate the




Four ESBL-producing E. coli isolates, recovered from
urine from standard patient care individuals with in-
dwelling urinary catheters and symptoms of UTI, were
obtained from the Department of Microbiology, Örebro
University hospital, Sweden. The identity of the patients
was anonymized and after that further analysis of the
bacterial strains was performed. Antimicrobial suscepti-
bility testing was performed as recommended by the
Swedish Reference Group for Antibiotics (www.folkhal
somyndigheten.se/raf ). The blaCTX-M gene was detected
using real time PCR and nucleotide sequencing as
previously described [21]. The CTX-M types and the
antibiotic susceptibility of the different ESBL-producing
E. coli are shown in Table 1.
UPEC strain J96, a pyelonephritis isolate, and an hmp-
deficient mutant of J96 (J96Δhmp) were also used in the
study. Deletion mutation of hmp was constructed using
homologous recombination and the FLP recombinase as
previously described [12]. There was no difference in the
growth ability (measurement of OD600 for 24 hours) be-
tween the mutant strain (J96Δhmp) and the wild type
strain (J96wt) [12]. Bacteria were maintained on tryptic
soy agar (TSA) (Becton Dickinson, Le Pont Claix, France).
Antimicrobial agents
All antimicrobial solutions were prepared freshly imme-
diately before use. DETA/NO belongs to the family of
diazeniumdiolates that consists of a complex of NO
bound to a polyamine parent compound that spontan-
eously decompose in a pH-dependent, first-order
process [22]. Stock solutions of DETA/NO (DETA/
NONOate, Alexis Biochemicals, Lausen, Schweiz) were
prepared in PBS (Invitrogen; Grand Island N.Y., USA),
cefotaxime and polymyxin B nonapeptid (PMBN; Sigma-
Aldrich, St. Louis, USA) were prepared in sterile water.
Nitrofurantoin (Sigma-Aldrich, St. Louis, USA) was pre-
pared in DMSO (Merck, Hohenbrunn, Germany) and
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solved in 25% ethanol (70%) and 75% polyetylenglykol
400 while heating for 1 h at 60°C.
Determination of MIC
MIC (minimum inhibitory concentration) was determined
by the broth dilution test. The test substances were inocu-
lated with a bacterial suspension (~ 106 CFU/ml) in Luria-
Bertani (LB) broth (Lennox, Becton Dickinson, Franklin
Lakes, USA) for 8–24 h at 37°C. All MIC tests were re-
peated in two isolates and at least twice. The MIC value
for cefotaxime was determined in a cephalosporin-
sensitive uropathogenic E. coli isolate. The MIC value for
DETA/NO was determined after 8 h since bacterial re-
growth was seen in all tubes after 24 h. A working concen-
tration of 4 × MIC was used in all experiments.
Evaluation of bacterial viability
An overnight culture grown in LB broth, at 37°C on
shake at 200 rpm, were diluted 1/1000 to give a bacterial
count of approximately 106 CFU/ml in the tube. Time-
zero samples (starting inoculums) were taken and the
number of viable colonies determined as described
below. Bacterial cultures were combined with antibiotics
or relevant vehicle and incubated in darkness at 37°C.
Samples were taken at different times after addition of
antibiotics or vehicle (2, 4, 8 and 24 h) depending on the
experimental protocol. The samples were diluted in PBS
and at least three serial dilutions were plated on TSA-
plates. Following overnight culture at 37°C, bacterial
CFU/ml was determined by using mean from two dilu-
tions. Growth was calculated as the numbers of CFU/ml
in treated cultures or controls divided by the number of
CFU/ml formed upon the plating of the initial starting
inoculums and expressed as log CFU/ml.
Experimental protocol
1) The bacterial viability of DETA/NO (4 × MIC,
4 mM), cefotaxime (4 × MIC, 0.26 μg/ml) and nitrofur-
antoin (4 × MIC, 32 μg/ml) was compared in all four
ESBL-producing isolates after 8 h of treatment. Two iso-
lates (ESBL 1 and ESBL 7) were further analysed at 2
and 4 h of treatment. 2) To confirm that the effect of
DETA/NO was caused by NO and not the parent com-
pound, a tube with DETA/NO in solution was inacti-
vated at 37°C for 96 h followed by exposure in open air
for 20 h. 3) To examine the involvement of the NO-
consuming enzyme flavohemoglobin, an hmp-deficient
UPEC strain (J96Δhmp) and the wild type J96 strain
were exposed to DETA/NO for 4, 8 and 24 h and the
viability evaluated. 4) The effect of the imidazole anti-
biotic miconazole (50 μM) in combination with DETA/
NO was examined in ESBL isolate 7 at 4, 8 and 24 h. 5)
PMBN (5 μg/ml), a compound that increases cellmembrane permeability [23], was examined in combin-
ation with miconazole and DETA/NO and the viability
evaluated in all four ESBL isolates and in J96Δhmp.
Statistical analysis
Data are expressed as mean ± SEM. Differences between
groups were assessed by the unpaired two-tailed Stu-
dent’s t-test. Results were considered statistically signifi-
cant at p < 0.05. n = number of independent biological
replicates.
Results
Characteristics of the isolates
Antibiotic susceptibility testing revealed that the four
isolates were resistant to cefotaxime, ceftazidime, tri-
methoprim and ciprofloxacin. In addition, resistance to
ceftibuten, mecillinam and gentamicin was detected in
some isolates (Table 1). Nucleotide sequencing revealed
that the included isolates were represented by the
CTX-M types CTX-M-15, CTX-M-14 and CTX-M-24
(Table 1).
The antibacterial effect of DETA/NO
The antibacterial effect of the NO-donor DETA/NO on
the ESBL-producing isolates was compared with the ef-
fect of the established antibiotics cefotaxime and nitro-
furantoin after exposure for 8 h. Untreated isolates
(controls) showed a growth of 2–3 log units during the
8 h period (Figure 1). As predicted, based on the anti-
biotic susceptibility tests, all four ESBL-producing iso-
lates were resistant to the β-lactam antibiotic cefotaxime
(Figure 1A), but sensitive to nitrofurantoin (Figure 1B).
The growth response in DETA/NO-treated isolates was
reduced by approximately 1–1.5 log units compared to
controls (Figure 1C). The ESBL isolates 1 and 7, repre-
senting the most and the least DETA/NO-sensitive iso-
lates were further evaluated by time-course studies after
exposure to DETA/NO, cefotaxime and nitrofurantoin
for 2, 4, and 8 h (Figure 2). In both isolates, DETA/NO
demonstrated a significant growth inhibition compared
to controls after 2 and 4 h of exposure (Figure 2). How-
ever, after 8 h the growth inhibitory effect was less pro-
nounced and only significant in ESBL isolate 7 (Figure 2).
A second dose of DETA/NO, administered after 4 h, did
not prolong the growth inhibition at 8 h (data not shown).
The effects of nitrofurantoin increased over time and, at
least in ESBL isolate 7, the effect was bactericidal (de-
crease in viability by > 103 log units) after 8 h. Both ESBL
isolates were resistant to cefotaxime at all time points
tested (Figure 2).
DETA/NO belongs to the family of diazeniumdiolates
and is a complex of NO bound to a polyamine parent
compound. An inactivated DETA/NO solution (pro-
longed heating and open air exposure) was found to lack
Figure 1 A comparison of the antibacterial effect of cefotaxim,
nitrofurantoin and DETA/NO. The effect of cefotaxim (A),
nitrofurantoin (B) and DETA/NO (C) on bacterial viability studied in
four different ESBL-producing isolates (ESBL 1, ESBL 6, ESBL 7, ESBL 9)
after exposure for 8 h. Growth is shown as log CFU/ml of treated bacteria
or controls (untreated) and compared to the initial starting inoculum.
Representative data from one experiment is shown and similar results
were obtained in at least two independent experiments for each isolate.
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verifying that the antibacterial effect of DETA/NO is
caused by NO.
Inhibition of flavohemoglobin by gene deletion
To examine the role of flavohemoglobin for the antibac-
terial effect evoked by DETA/NO an hmp-deficient UPEC
strain (J96Δhmp) was used. The growth response of un-
treated J96Δhmp and the wild type strain did not differ
during the experimental period of 24 h (Figure 3). How-
ever, the J96Δhmp strain showed a more prolonged
growth inhibition in response to DETA/NO compared to
wild type J96 (p < 0.001 at 8 h; Figure 3). The growth of
the hmp-deficient strain recovered after 24 h (Figure 3).Pharmacological modulation of the antibacterial effect of
DETA/NO
The imidazole antimicrobial agent miconazole was used
to examine whether pharmacological inhibition of flavo-
hemoglobin affects the antibacterial effects of DETA/
NO. Miconazole (50 μM) per se had small effects on the
growth response when compared to controls (Figure 4A).
When DETA/NO and miconazole were combined, the
growth inhibition at 8 h was significantly more pro-
nounced (p < 0.001) for the combination treatment than
for DETA/NO alone (Figure 4B). However, after 24 h the
differences in growth between the treatments were small
and overall the viability was not significantly different
from the untreated controls (Figure 4B).
Hydrophobic antibiotics, like miconazole, have poor cell
membrane permeability in gram-negative bacteria. Poly-
myxin B antibiotics, like polymyxin B nonapeptide (PMBN),
can be used to increase the bacterial cell wall permeability
of E. coli [23]. Time-course studies showed that PMBN
(5 μg/ml) per se had no effect on the bacterial viability at 4,
8 or 24 h (Figure 4A). In MIC studies, PMBN had no effect
on bacterial growth at the highest concentration tested
(64 μg/ml). Miconazole and PMBN were used in concentra-
tions that per se had no or minor effect on bacterial viability
(Figure 4A). When DETA/NO was combined with micona-
zole and PMBN a marked and prolonged bacteriostasis
for up to 24 h (p < 0.001) was noted in ESBL isolate 7
(Figure 4C). A prolonged bacteriostasis after treatment of
DETA/NO in combination with miconazole and PMBN
was also noted in ESBL isolates 6 (p < 0.01) and 9 (p < 0.01),
while the effect was less pronounced in ESBL isolate 1 (p <
0.05; Figure 5A). PMBN and miconazole in combination
slightly reduced the bacterial growth (Figure 5A). DETA/
NO and PMBN in combination showed full recovery of
growth after 24 h (data not shown).
The effect of miconazole in the hmp-deficient UPEC strain
To investigate whether the effect of miconazole can be ex-
plained by inhibition of flavohemoglobin, miconazole
was further evaluated in the hmp-deficient UPEC strain
(J96Δhmp). This strain does not express the flavohemoglo-
bin protein and should therefore be insensitive to pharma-
cological inhibition of flavohemoglobin. As previously
noted (Figure 3), DETA/NO inhibited the growth of the
hmp-deficient UPEC during the 8 h study period. The
addition of miconazole did not further enhance the growth
inhibitory response evoked by DETA/NO (Figure 5B). The
inhibitory effect of miconazole and DETA/NO in combin-
ation with PMBN was not significantly different from the
effect by DETA/NO alone (Figure 5B).
Discussion
The present study investigated the antibacterial effects
of NO in multidrug-resistant ESBL-producing isolates
Figure 2 Time-course studies of the antibacterial effect of cefotaxim, nitrofurantoin and DETA/NO. Time-course study of cefotaxim,
nitrofurantoin and DETA/NO on bacterial viability studied in (A) ESBL-producing isolate 1 and (B) ESBL-producing isolate 7 after exposure for 2,
4 and 8 h. Growth is shown as log CFU/ml of treated bacteria or controls (untreated) and compared to the initial starting inoculum. Data are
expressed as mean ± SEM of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs control.
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enzyme flavohemoglobin. Measuring bacterial sensitivity
to gaseous NO is difficult because NO per se is stable
for only minutes under physiological conditions [24]. In-
stead, NO-releasing compounds e.g., DETA/NO can be
added to bacterial cultures to evaluate the growthFigure 3 The antibacterial effect of DETA/NO in a mutant strain lackin
bacterial viability in an hmp-deficient UPEC strain (Δhmp) and a wild type (
log CFU/ml of treated bacteria or controls (untreated) and compared to th
independent experiments. ***p < 0.001 DETA/NO wt vs DETA/NO Δhmp.response. In E. coli, NO acts in a bacteriostatic fashion
and its targets include respiratory enzymes like cyto-
chromes bo and bd and biosynthesis pathways of
branched-chain amino acid [25]. In our study, DETA/
NO induced a temporary growth inhibition in ESBL-
producing UPEC isolates but after 8 hours of DETA/NOg the flavohemoglobin gene (hmp). The effect of DETA/NO on
wt) UPEC strain after exposure for 4, 8 and 24 h. Growth is shown as
e initial starting inoculum. Data are expressed as mean ± SEM of three
Figure 4 The antibacterial effect of DETA/NO in combination with miconazole and polymyxin B nonapeptide. The effect of DETA/NO on
bacterial viability when combined with miconazole and polymyxin B nonapeptide (PMBN) in ESBL-producing isolate 7 after exposure for 4, 8 and
24 h. Growth is shown as log CFU/ml of treated bacteria or controls (untreated) and compared to the initial starting inoculum. (A) The effects of
miconazole and PMBN per se are shown. *p < 0.05 control vs miconazole (B) The effects of DETA/NO alone and in combination with miconazole
are shown. ***p < 0.001 DETA/NO vs DETA/NO +miconazole (C) The effects of DETA/NO alone and DETA/NO in combination with miconazole
and PMBN are shown. **p <0.01, ***p < 0.001 DETA/NO vs DETA/NO +miconazole + PMBN. All data are expressed as mean ± SEM of three-four
independent experiments.
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of DETA/NO, administered after 4 hours, did not pro-
long the growth inhibition (data not shown), suggesting
that stress-response factors and NO-defence mecha-
nisms may have been activated by the first dose. All iso-
lates were resistant to cefotaxime but nitrofurantoin
showed a time-dependent bactericidal effect. Nitrofuran-
toin is an antibiotic used for treatment of uncomplicated
UTIs, and is so far effective against many isolates of
ESBL-producing E. coli [26].
Upon diffusing into the bacteria, NO may react with
Fe-S clusters, undergo autoxidation or be consumed dir-
ectly through enzymatic detoxification [4]. Under aer-
obic conditions the vast majority of intracellular NO inE. coli is consumed through flavohemoglobin detoxifica-
tion [4,9,10]. The flavohemoglobin enzyme is not consti-
tutively expressed and needs to be induced by gene
transcription [9,10]. We have previously shown that uro-
pathogenic E. coli increase gene and protein expression
of flavohemoglobin after exposure to DETA/NO [6,12].
Thus, induction of the flavohemoglobin enzyme and a fast
consumption of NO to submicromolar intracellular NO
concentrations may explain the temporary growth inhib-
ition with a subsequent growth recovery in our experi-
ments. Indeed, a mutant strain lacking the flavohemoglobin
enzyme (J96Δhmp) showed prolonged inhibition of growth,
but after 24 hours this mutant also showed resumed
growth. It has previously been verified that the hmp-
Figure 5 The antibacterial effect of DETA/NO in combination with miconazole and polymyxin B nonapeptide in three additional ESBL-
producing isolates and in a mutant strain lacking the flavohemoglobin gene (hmp). (A) The effect of DETA/NO on bacterial viability when
combined with miconazole and polymyxin B nonapeptide (PMBN) in three additional ESBL-producing isolates (ESBL 1, ESBL 6, ESBL 9) after exposure
for 24 h. *p < 0.05, **p < 0.01, ***p < 0.001 vs control, †p <0.05 DETA/NO+miconazole + PMBN vs PMBN+miconazole. (B) The effect of DETA/NO on
bacterial viability when combined with miconazole and polymyxin B nonapeptide (PMBN) in an hmp-deficient UPEC strain (Δhmp) after exposure for
8 h. Growth is shown as log CFU/ml of treated bacteria or controls (untreated) and compared to the initial starting inoculum. Data are expressed as
mean ± SEM of three independent experiments.
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the flavohemoglobin gene or protein when exposed to
DETA/NO [12]. In the absence of functional flavohemoglo-
bin NO is predicted to be metabolized mainly through aut-
oxidation, enzymatic reduction by NorV and NrfA and by
Fe-S nitrosylation [4]. Inhibition of flavohemoglobin by
gene deletion was performed in a non ESBL-producing
UPEC strain (J96). Gene deletion in ESBL-producing iso-
lates is hampered by the obvious difficulties to find se-
lection antibiotics in these multidrug-resistant isolates.
However, we have confirmed a marked increase in hmp
expression in an ESBL-producing isolate by real time RT-
PCR when exposed to DETA/NO (data not shown), con-
firming that hmp is induced by DETA/NO also in ESBL-
producing isolates.
Miconazole is known to interfere with synthesis of fungal
and bacterial lipid membranes as it restrains the ergosterol
synthesis [27], but recent studies also suggest that azole an-
tibiotics target the flavohemoglobin enzyme [14,15]. Mi-
conazole in combination with DETA/NO prolonged the
DETA/NO-induced growth inhibition in ESBL-producing
UPEC isolates. Notably, the pattern of DETA/NO-evoked
growth inhibition achieved by addition of miconazole
was similar to the pattern noted after hmp-deletion.Furthermore, the fact that miconazole did not increase the
DETA/NO-induced growth inhibition in an hmp-mutant
strain, support that inhibition of flavohemoglobin [14] con-
tributes to the antibacterial effect of miconazole in our ex-
periments. Thus, the prolonged growth inhibition evoked
by DETA/NO and miconazole in combination may be a re-
sult of interactions of miconazole with flavohemoglobin,
causing both inhibition of NO dioxygenase activity and oxi-
dative stress following high levels of cytotoxic superoxide
production [14,15]. In agreement with our results, intracel-
lular survival studies in activated NO-producing macro-
phages demonstrated decreased survival of miconazole-
treated S. aureus compared to untreated bacteria [15].
DETA/NO and miconazole have a synergistic antifungal
effect in Candida species [28], and the present study dem-
onstrates that these two compounds also caused an en-
hanced antibacterial effect against multidrug-resistant
ESBL-producing E. coli isolates.
It is noteworthy that inhibition of flavohemoglobin ac-
tivity by miconazole is more pronounced in purified en-
zyme than in intact E. coli [14], in line with the poor
membrane permeability of E. coli to imidazole antibiotics
[29]. Polymyxin B antibiotics may be used to sensitize the
outer membrane of gram-negative bacteria to hydrophobic
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(PMBN), a compound that increases the cell permeability
in E. coli without affecting the bacterial viability [23,30], to
avoid that polymyxin B mask the antibacterial effects of
NO. PMBN per se had no antibacterial effect, while mi-
conazole at the concentration used showed a minor in-
hibitory effect on UPEC growth. An in vitro synergism of
miconazole and polymyxin B has been reported in E. coli,
related predominantly to the ability of polymyxin B to in-
crease the penetration of miconazole to the intracellular
space [31]. In our experiments, miconazole and PMBN in
combination caused a significant inhibition of growth
compared to untreated controls. Interestingly, when
DETA/NO was added to miconazole and PMBN a pro-
longed bacteriostatic response that persisted for 24 hours
was observed. It is not likely that the underlying mechan-
ism is a more effective inhibition of NO-detoxification by
flavohemoglobin since the hmp-mutant showed recovered
growth after 24 hours. However, a better access of micona-
zole to intracellular targets like flavohemoglobin, when
combined with PMBN, may cause enhanced antibacterial
activity through magnification of intracellular oxidative
stress responses [15]. Furthermore, increased formation of
toxic peroxynitrite (ONOO−), a potent oxidant formed
from NO and superoxide radical [1], could conceivably
contribute to the spectrum of potential antibacterial
mechanisms of the combination treatment. The bacterial
cell membrane is another possible target and miconazole
is known to affect the integrity of the lipid membrane
[27,32]. Morphological analysis have revealed cell mem-
brane deteriorations with widespread structural deforma-
tions as a consequence of NO exposure in E. coli [33], and
a synergistic effect of all three substances on the cell mem-
brane is possible. However, the exact mechanisms for the
prolonged bacteriostasis evoked by DETA/NO in combin-
ation with miconazole and PMBN need to be further stud-
ied. Interestingly, impaired adhesion to host renal epithelial
cells and broken fimbriae has been reported after NO ex-
posure in E. coli [33,34]. This suggests that the antibacterial
effects of NO may be widespread and that NO not only has
growth inhibitory effects but also may affect bacterial viru-
lence properties and host activating mechanisms.
The ESBL-producing UPEC isolates used in the
present study were obtained from patients with catheter-
associated UTI. Indwelling medical devices, including
urinary catheters and biofilm formation increase the risk
of bacterial infection and result in considerable anti-
microbial use. When these infections are caused by
multidrug-resistant bacteria commonly used empirical
antimicrobial therapy are not effective [35]. Administra-
tion of NO directly into the bladder through a silicone
balloon catheter represents a local delivery system for
NO-based therapy and has been suggested as one strat-
egy to prevent catheter-associated infections [5]. Urinarycatheters impregnated with NO have been shown to in-
hibit both biofilm formation and planktonic E. coli
growth [36]. A limitation of the present study is that the
number of clinical isolates used is small. However, three
out of four isolates responded identical and with a pro-
longed bacteriostasis to the triple combination. These
clinical isolates represented different CTX-M enzymes
but it is, however, not possible to draw any conclusions
on possible correlations between susceptibility to treat-
ment and the CTX-M enzyme based on this material.
Importantly, two of the isolates belonged to the CTX-
M-15 ESBL type and the sequence type 131 (data not
shown) which represent the dominating worldwide emer-
ging CTX-M type and clone in community-acquired UTIs
[37,38].
Colistin, a polymyxin antibiotic, has regained interest
for its activity against multidrug-resistant gram negative
pathogens, including those harbouring carbapenamases
[39]. Thus, the emergency of multi-resistant pathogens
encourages rediscovery of older antibiotics with activity
against these resistant bacteria and in new combinations.
Our data suggest that two existing antibiotics, an azole
antifungal and a polymyxin B compound, are able to en-
hance the antimicrobial effects of exogenously adminis-
tered NO. In contrast to antibiotics that are specific to
one or few bacterial species, the antibacterial effects of
NO are broad and both gram-positive and gram-
negative pathogens, including antibiotic-resistant isolates
show sensitivity [40,41]. Development of resistance
mechanisms to NO may be limited by its multiple bio-
chemical targets, but metabolic adaptions to nitrosative
stress including induction of flavohemoglobin [10] and
lactate dehydrogenase in S. aureus [42] decrease the
antimicrobial action of NO. Therefore, as highlighted in
the present study, a combination treatment where ex-
ogenous NO is combined with an inhibitor of NO-
protective mechanisms appears to be an attractive ap-
proach to improve the antimicrobial effects of NO.
Conclusion
This work shows that the antibacterial effect of NO
against multidrug-resistant ESBL-producing uropatho-
genic E. coli is improved by combination with micona-
zole and polymyxin B nonapeptide.
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